)
Visual
earnings real time
Ventyx Biosciences (VTYX) investor relations material
Ventyx Biosciences Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary3 Dec, 2025
Program updates and clinical development
Interim data for VTX2735 in recurrent pericarditis (RP) shifted from December to 1Q to focus on once-daily (QD) dosing, aiming for a more robust dataset and seamless phase III transition.
Protocol amendments allow new patients to start directly on QD dosing, with ongoing safety monitoring up to 24 weeks and a target enrollment of up to 30 patients.
Expansion of trial sites in Canada, EU, and UK is underway to accelerate recruitment and facilitate future phase III studies.
Phase III is planned for the second half of the year, with no anticipated delays from the interim data shift.
Key efficacy endpoints are CRP normalization and rapid, sustained pain reduction, aiming to match or exceed Arcalyst’s profile.
Market opportunity and competitive landscape
The US pericarditis market includes 160,000 patients, with 14,000 severe cases; Arcalyst currently serves about 1,800 severe patients.
Arcalyst’s annual WAC pricing exceeds $300,000, and a once-daily oral alternative could offer significant pricing and market flexibility.
Current standard of care is weekly infusion, with future plans for less frequent injections; a daily oral therapy would be a major differentiator.
Severe RP is defined as three or more recurrences per year, with high unmet need for effective, convenient therapies.
The company’s market cap is $700 million, compared to Kiniksa’s $4 billion, highlighting growth potential.
Pipeline strategy and partnerships
The NLRP3 portfolio includes VTX2735 for RP and VTX3232 for CNS and cardiovascular indications, with a right of first negotiation (ROFN) agreement with Sanofi on VTX3232.
Sanofi’s ROFN is triggered by delivery of two data packages and is expected to resolve within months.
If Sanofi does not opt in, alternative partnerships or internal development for VTX3232, especially in cardiovascular indications, are under consideration.
The company aims to own the NLRP3 space, with flexibility to pivot compounds into multiple indications based on emerging data.
Ongoing planning includes potential expansion into additional inflammatory and cardiovascular diseases.
What VTX2735 pain score reduction is competitive?
VTX3232 strategy if Sanofi doesn't opt-in?
How does EU/UK site expansion accelerate VTX2735 P3?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ventyx Biosciences earnings date
Q4 202527 Feb, 2026
Next Ventyx Biosciences earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel oral therapies designed to treat patients with autoimmune and inflammatory disorders. The company's approach involves selectively modulating key immune targets to create differentiated medicines. Ventyx Biosciences is working on several promising drug candidates, including a selective allosteric tyrosine kinase type 2 inhibitor and a sphingosine 1 phosphate receptor modulator, which are in various stages of clinical trials targeting conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Additionally, they are developing inhibitors targeting the NLRP3 inflammasome. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage